Status:
COMPLETED
A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.
Lead Sponsor:
Sosei
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
AD 452 is a new drug which is being developed for use in adult patients with RA. It is believed that AD 452 may modify the underlying disease of RA as well as improving RA symptoms, and in order to es...
Eligibility Criteria
Inclusion
- Male/female age 18 -75
- RA diagnosed for at least 6 months
- Taking methotrexate for at least 6 months
- Must have at least 4 swollen/tender joints
Exclusion
- Must not be pregnant/breastfeeding
- Must not have history of other inflammatory disorders
- Other conditions may lead to exclusion from the trial (e.g. Diabetes mellitus, malignant melanoma, HIV, active infection, hepatitis B/C, cardiac conduction disorders, hepatic/renal insufficiency, active depression/anxiety/psychosis/schizophrenia or convulsions.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
232 Patients enrolled
Trial Details
Trial ID
NCT00141934
Start Date
August 1 2005
Last Update
April 5 2007
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research of West Florida, Inc
Clearwater, Florida, United States, 33765
2
Center for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida, United States, 33334
3
Ocala Rheumatology Research Center
Ocala, Florida, United States, 34474
4
Sarasota Arthritis Research Center
Sarasota, Florida, United States, 34239